Poster board nr
Abstract nr
Genitourinary Malignancies
Proffered Paper Session: Genitourinary Malignancies – Prostate Cancer
Chair: M. Hoyer (Denmark)
Chair: M. Hoyer (Denmark)
Chair: R. Cathomas (Switzerland)
Chair: R. Cathomas (Switzerland)
10:30
2500
Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)
R. Cathomas, S. Crabb, H. Kenner, M. Mark, C. Rothermundt, T. Elliott, R. Winterhalder, P. Von Burg, S. Berardi Vilei, S. Hayoz, D. Rauch, E. Roggero, F. Stenner, D. Berthold, A. Erdmann, N. Fischer, G. Manetsch, S. Gillessen
10:45
2501
A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer
B. Montgomery, A. Joshua, M. Gleave, N. Fleshner, G. Bubley, L. True, M. Tretiakova, K. Wu, W. Novotny, A. Peterson, A. Amelsberg, M.E. Taplin
11:00
2502
TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)
N. Shore, J. Bailen, C. Pieczonka, D. MacLean, H. Shi, H. Faessel, F. Saad
11:15
Discussant : B. Tombal (Belgium)
11:25
2503
Hypermethylation of a specific area in the TERT promoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy
P. Castelo-Branco, R. Leão, R.A. De Mello, T. Lipman, B. Campbell, A. Price, C. Zhang, S. Buerno, A. Gomes, R.G. Bristow, M. Schweiger, R. Hamilton, A. Zlotta, A. Figueiredo, H. Klocker, H. Sueltmann, U. Tabori
11:40
2504
Genomic predictive and prognostic factors from plasma cell-free DNA (cfDNA) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) commencing enzalutamide (ENZ)
K. Chi, A. Azad, S. Volik, A. Haegert, S. Le Bihan, B. McConeghy, M. Gleave, A. Wyatt, C. Collins
11:55
2505
TMPRSS2-ERG in blood and docetaxel response in metastatic castration-resistant prostate cancer
O. Reig, M. Marín-Aguilera, G. Carrera, N. Jiménez, S. García-Recio, L. Gaba, M.V. Pereira, P. Fernandez, A. Prat, B. Mellado
12:10
Discussant : H. Scher (USA)